Org 36286 in Participants Undergoing Repeated Controlled Ovarian Stimulation Cycles Using a Multiple Dose GnRH Antagonist Protocol (Study 38825)(P05714)(COMPLETED) (Trust)

This study has been completed.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: June 11, 2008
Last updated: January 24, 2014
Last verified: January 2014

The objective of the trial is to assess the non-immunogenicity and safety of Org 36286 in participants undergoing repeated Controlled Ovarian Stimulation (COS) cycles using a multiple dose GnRH antagonist protocol.

Condition Intervention Phase
In Vitro Fertilization
Drug: Org 36286
Drug: Follicle stimulating hormone (FSH)
Drug: Gonadatropin releasing horming (GnRH)
Drug: Recombinant human chorionic gonadatropin (rec[hCG])
Drug: Progesterone
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase III, Uncontrolled Trial to Assess the Non-immunogenicity and Safety of Org 36286 in Patients Undergoing Repeated Controlled Ovarian Stimulation Cycles Using a Multiple Dose GnRH Antagonist Protocol

Resource links provided by NLM:

Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Main safety parameters: anti-Org 36286 antibodies, local tolerance, occurrence of (S)AEs and occurrence of moderate to severe OHSS. [ Time Frame: A maximum of 3 COS cycles. ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Amount of (rec)FSH needed from stimulation day 8 onwards to reach the criterion for administration of (rec)hCG [ Time Frame: A maximum of 3 COS cycles. ] [ Designated as safety issue: No ]
  • Number and size distribution of follicles (>= 11 mm, >= 15 mm, and >= 17 mm) as documented by ultrasonography from stimulation day 1 up to and including the day of (rec)hCG administration; Number and quality of oocytes retrieved [ Time Frame: A maximum of 3 COS cycles. ] [ Designated as safety issue: No ]
  • Number of fertilized oocytes obtained, frozen and used for embryo development; Fertilization rate, defined as the ratio of the number of fertilized 2PN oocytes obtained and the number of oocytes incubated (IVF or ICSI) [ Time Frame: A maximum of 3 COS cycles. ] [ Designated as safety issue: No ]
  • Implantation rate for subjects with ET (defined as 100 times the number of gestational sacs as assessed by the first USS after ET divided by the number of embryos transferred for each subject) [ Time Frame: A maximum of 3 COS cycles. ] [ Designated as safety issue: No ]
  • Biochemical pregnancy, ectopic pregnancy, clinical pregnancy, vital pregnancy, (singleton and multiple) ongoing pregnancy and miscarriage; Outcome of FTET cycles; Cumulative ongoing pregnancy rate. [ Time Frame: A maximum of 3 COS cycles. ] [ Designated as safety issue: No ]
  • Number and quality of embryos obtained, transferred and frozen [ Time Frame: A maximum of 3 COS cycles. ] [ Designated as safety issue: No ]
  • Endocrinological parameters (FSH, LH, E2, P, inhibin-B) as determined by central lab, during stimulation and including the day of (rec)hCG administration, at embryo transfer and 2 weeks after embryo transfer [ Time Frame: A maximum of 3 COS cycles. ] [ Designated as safety issue: No ]

Enrollment: 682
Study Start Date: September 2006
Study Completion Date: April 2009
Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Org 36286 150 µg
A single dose of 150 µg Org 36286 will be administered subcutaneously on day 2-3 of the menstrual cycle. Administration of the GnRH antagonist will start on stimulation day 5 or 6. From stimulation day 8 onwards, treatment is continued with a daily dose of any commercially available FSH-containing preparation up to the day of (rec)hCG administration. Administration of the FSH-containing preparation on the day of hCG is optional. The investigator may withhold gonadotropin administration for a maximum of 3 days (coasting) up to and including the day of (rec)hCG administration. The maximum total duration of stimulation is 19 days.
Drug: Org 36286
Org 36286 150 µg administered as a single subcutaneous dose.
Other Name: corifollitropin alfa
Drug: Follicle stimulating hormone (FSH)
FSH administerd subcutaneously at a dose not to exceed 225 IU/day.
Drug: Gonadatropin releasing horming (GnRH)
GnRH administered subcutaneouslyat a dose of 0.25 mg/day.
Drug: Recombinant human chorionic gonadatropin (rec[hCG])
Rec(hCG) administered subcutaneously at a dose of 5,000-10,000 IU/250 µg.
Drug: Progesterone
Progesterone administered vaginally at a dose of at lat 600 mg/day.

Detailed Description:

This trial is designed as an open-label, uncontrolled, repeated cycle trial to assess the non-immunogenicity and safety of Org 36286 in participants undergoing repeated controlled ovarian stimulation (COS) cycles for in vitro fertilization

(IVF) or intracytoplasmic sperm injection (ICSI) using a multiple dose GnRH antagonist protocol. The trial period per participant will cover 1, 2 or 3 treatment cycles and no more than three (in-between two stimulation cycles) Frozen-Thawed Embryo Transfer (FTET) cycles from the first two treatment cycles. In each stimulation cycle, participants receive a single injection of Org 36286 and one week later, treatment is continued with a daily dose of any FSH-containing preparation up to the day of (rec)hCG administration for final oocyte maturation. Assessment of anti-Org 36286 antibodies and local tolerance after Org 36286 injection are important safety endpoints in this trial.


Ages Eligible for Study:   18 Years to 39 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Females of couples with an indication for COS and IVF or ICSI;
  • >=18 and <=39 years of age at the time of signing informed consent;
  • Body weight > 60 kg and BMI >=18 and <=29 kg/m^2;
  • Normal menstrual cycle length: 24-35 days;
  • Availability of ejaculatory sperm (use of donated and/or cryopreserved sperm is allowed);
  • Willing and able to sign informed consent.

Exclusion Criteria:

  • History of or any current (treated) endocrine abnormality;
  • History of ovarian hyper-response or history of ovarian hyperstimulation syndrome (OHSS);
  • History of or current polycystic ovary syndrome (PCOS);
  • More than 20 basal antral follicles (size: <11 mm, both ovaries combined) as

measured on USS in the early follicular phase (menstrual cycle day 2-5);

  • Less than 2 ovaries or any other ovarian abnormality, including endometrioma

> 10 mm (visible on USS);

  • Presence of unilateral or bilateral hydrosalpinx (visible on USS);
  • More than three unsuccessful COS cycles since the last established ongoing

pregnancy (if applicable);

  • History of non- or low ovarian response to FSH/hMG treatment;
  • FSH > 12 IU/L or LH > 12 IU/L as measured by the local laboratory (sample taken during the early follicular phase: menstrual cycle day 2-5);
  • Any clinically relevant abnormal laboratory value based on a sample taken during the screening phase (including abnormal cervical smear (PAP>=III, CIN>=1));
  • Contraindications for the use of gonadotropins (e.g. tumors, pregnancy/lactation, undiagnosed vaginal bleeding, hypersensitivity, ovarian cysts) or GnRH antagonists (e.g. hypersensitivity, pregnancy/lactation);
  • Recent history of or current epilepsy, HIV infection, thrombophilia, diabetes or cardiovascular, gastro-intestinal, hepatic, renal, or pulmonary disease;
  • Abnormal karyotyping of the patient or her partner (if karyotyping is performed);
  • History or presence of alcohol or drug abuse within 12 months prior to signing informed consent;
  • Previous use of Org 36286;
  • Use of hormonal preparations within 1 month prior to screening;
  • Administration of investigational drugs within three months prior to signing informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided by Merck Sharp & Dohme Corp.

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00696878     History of Changes
Other Study ID Numbers: P05714, P05714, 2004-004966-34
Study First Received: June 11, 2008
Last Updated: January 24, 2014
Health Authority: Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Australia: Department of Health and Ageing Therapeutic Goods Administration
Brazil: National Health Surveillance Agency
Chile: Instituto de Salud Pública de Chile
Denmark: Danish Medicines Agency
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: German Institute of Medical Documentation and Information
Hungary: National Institute of Pharmacy
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Norway: Norwegian Medicines Agency
Sweden: Medical Products Agency
United States: Food and Drug Administration

Keywords provided by Merck Sharp & Dohme Corp.:
Pharmacological effects of drugs
Hormones, Hormone Substitutes and Hormone Antagonists
Pharmacological Actions

Additional relevant MeSH terms:
Follicle Stimulating Hormone
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Progestins processed this record on April 19, 2015